<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36875205</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022.</ArticleTitle><Pagination><StartPage>e13107</StartPage><MedlinePgn>e13107</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13107</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.13107</ELocationID><Abstract><AbstractText Label="BACKGROUND">Bacterial and viral infections can occur with SARS-CoV-2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood.</AbstractText><AbstractText Label="METHODS">We used the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection between March 2020 and April 2022. Clinician-driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non-SARS-CoV-2 endemic coronaviruses.</AbstractText><AbstractText Label="RESULTS">Among 36 490 hospitalized adults with COVID-19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co-morbidities, bacterial infections in patients with COVID-19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing. <i>Staphylococcus aureus</i> and Gram-negative rods were the most frequently isolated bacterial pathogens. Among hospitalized adults with COVID-19, 2766 (7.6%) were tested for seven virus groups. A non-SARS-CoV-2 virus was identified in 0.9% of tested patients.</AbstractText><AbstractText Label="CONCLUSIONS">Among patients with clinician-driven testing, 6.0% of adults hospitalized with COVID-19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.</AbstractText><CopyrightInformation>© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Melisa M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-7277-1547</Identifier><AffiliationInfo><Affiliation>Epidemic Intelligence Service Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>COVID-19 Emergency Response Team Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Kadam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>COVID-19 Emergency Response Team Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Dynamics Information Technology Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milucky</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1491-4669</Identifier><AffiliationInfo><Affiliation>COVID-19 Emergency Response Team Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>COVID-19 Emergency Response Team Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reingold</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>California Emerging Infections Program Oakland California USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of California, Berkely Berkely California USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armistead</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Colorado Department of Public Health &amp; Environment Denver Colorado USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meek</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Connecticut Emerging Infections Program Yale School of Public Health New Haven Connecticut USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Evan J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0002-1576-4420</Identifier><AffiliationInfo><Affiliation>Departments of Medicine and Pediatrics Emory University School of Medicine Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Georgia Emerging Infections Program, Georgia Department of Public Health Atlanta Veterans Affairs Medical Center Atlanta Georgia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigel</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Iowa Department of Health Des Moines Iowa USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reeg</LastName><ForeName>Libby</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Michigan Department of Health and Human Services Lansing Michigan USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Como-Sabetti</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Minnesota Department of Health Saint Paul Minnesota USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ropp</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>New Mexico Department of Health Santa Fe New Mexico USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muse</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>New York State Department of Health Albany New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bushey</LastName><ForeName>Sophrena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine and Dentistry Rochester New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiltz</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ohio Department of Health Columbus Ohio USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutton</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Public Health Division Oregon Health Authority Portland Oregon USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>H Keipp</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center Nashville Tennessee USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatelain</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Salt Lake County Health Department Salt Lake City Utah USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havers</LastName><ForeName>Fiona P</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>COVID-19 Emergency Response Team Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta Georgia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>US Public Health Service Commissioned Corps Rockville Maryland USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CDC COVID‐NET Surveillance Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NU38OT000297</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001424" MajorTopicYN="Y">Bacterial Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">COVID‐NET</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">bacterial coinfection</Keyword><Keyword MajorTopicYN="N">viral coinfection</Keyword></KeywordList><CoiStatement>Ms. Leegwater and Ms. Reeg report grants from Michigan Department of Health and Human Services during the conduct of the study. Dr. Anderson reports grants from Pfizer, Merck, PaxVax, Micron, Sanofi‐Pasteur, Janssen, MedImmune, and GSK. Dr. Anderson reports personal fees from Sanofi‐Pasteur, Pfizer, Medscape, Kentucky Bioprocessing, Inc, Sanofi‐Pasteur, Janssen, GSK, WCG and ACI Clinical, and Moderna outside the submitted work. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID‐19 vaccines. Mr. Weigel reports grants from CDC/CSTE Cooperative Agreement, during the conduct of the study and grants from CDC/CSTE outside the submitted work. Mr. Teno reports grants from CDC/CSTE Cooperative Agreement during the conduct of the study and grants from CDC/CSTE outside the submitted work. Mrs. Billing reports grants from Council of State and Territorial Epidemiologists (CSTE) during the conduct of the study and grants from Centers for Disease Control and Prevention (CDC) outside the submitted work. Mr. Meek reports grants from CDC during the conduct of the study. Dr. Schaffner reports grants from CDC during the conduct of the study. Dr. Sutton reports grants from CDC Emerging Infections Program during the conduct of the study. Dr. Talbot reports grants from Centers for Disease Control and Prevention, during the conduct of the study. Ms. Yousey‐Hindes reports grants from CDC during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36875205</ArticleId><ArticleId IdType="pmc">PMC9981874</ArticleId><ArticleId IdType="doi">10.1111/irv.13107</ArticleId><ArticleId IdType="pii">IRV13107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community‐acquired pneumonia in adults. Thorax. 2008;63(1):42‐48. doi:10.1136/thx.2006.075077</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.2006.075077</ArticleId><ArticleId IdType="pubmed">17573440</ArticleId></ArticleIdList></Reference><Reference><Citation>Swets MC, Russell CD, Harrison EM, et al. SARS‐CoV‐2 co‐infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet Published online. 2022;399(10334):S014067362200383X. doi:10.1016/S0140-6736(22)00383-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00383-X</ArticleId><ArticleId IdType="pmc">PMC8956294</ArticleId><ArticleId IdType="pubmed">35344735</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell K, Fowlkes A, Lynfield R, et al. Viral and bacterial co‐detections in influenza‐positive patients hospitalized with severe acute respiratory illness—Minnesota, 2013–2015. Open Forum Infect Dis. 2016;3(suppl_1):1754. doi:10.1093/ofid/ofw194.134</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofw194.134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rynda‐Apple A, Robinson KM, Alcorn JF. Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. Infect Immun. 2015;83(10):3764‐3770. doi:10.1128/IAI.00298-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00298-15</ArticleId><ArticleId IdType="pmc">PMC4567631</ArticleId><ArticleId IdType="pubmed">26216421</ArticleId></ArticleIdList></Reference><Reference><Citation>Melvin JA, Bomberger JM. Compromised defenses: exploitation of epithelial responses during viral‐bacterial co‐infection of the respiratory tract. PLoS Pathog. 2016;12(9):e1005797. doi:10.1371/journal.ppat.1005797</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005797</ArticleId><ArticleId IdType="pmc">PMC5025022</ArticleId><ArticleId IdType="pubmed">27631788</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NS, Greenberg JA, McNulty MC, et al. Bacterial and viral co‐infections complicating severe influenza: incidence and impact among 507 U.S. patients, 2013–14. J Clin Virol. 2016;80:12‐19. doi:10.1016/j.jcv.2016.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2016.04.008</ArticleId><ArticleId IdType="pmc">PMC7185824</ArticleId><ArticleId IdType="pubmed">27130980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury L, Lim B, Baskaran V, Lim WS. Co‐infections in people with COVID‐19: a systematic review and meta‐analysis. J Infect. 2020;81(2):266‐275. doi:10.1016/j.jinf.2020.05.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.046</ArticleId><ArticleId IdType="pmc">PMC7255350</ArticleId><ArticleId IdType="pubmed">32473235</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford BJ, So M, Raybardhan S, et al. Bacterial co‐infection and secondary infection in patients with COVID‐19: a living rapid review and meta‐analysis. Clin Microbiol Infect. 2020;26(12):1622‐1629. doi:10.1016/j.cmi.2020.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.016</ArticleId><ArticleId IdType="pmc">PMC7832079</ArticleId><ArticleId IdType="pubmed">32711058</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC
. Coronavirus Disease 2019 (COVID‐19)‐Associated Hospitalization Surveillance Network (COVID‐NET): Purpose and Methods. 2021.  12/03/2021. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html
</Citation></Reference><Reference><Citation>O'Halloran A, Whitaker M, Patel K, et al. Developing a sampling methodology for timely reporting of population‐based COVID‐19‐associated hospitalization surveillance in the United States, COVID‐NET 2020–2021. Influenza Resp Viruses. 2023;17(1):e13089. doi:10.1111/irv.13089</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13089</ArticleId><ArticleId IdType="pmc">PMC9835436</ArticleId><ArticleId IdType="pubmed">36625234</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S, Patel K, Pham H, et al. Clinical trends among U.S. adults hospitalized with COVID‐19, March to December 2020: a cross‐sectional study. Ann Intern Med. 2021;174(10):1409‐1419. doi:10.7326/M21-1991</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1991</ArticleId><ArticleId IdType="pmc">PMC8381761</ArticleId><ArticleId IdType="pubmed">34370517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Johansson N, Ternhag A, Abdel‐Halim L, Hedlund J, Nauclér P. Bacterial co‐infections in community‐acquired pneumonia caused by SARS‐CoV‐2, influenza virus and respiratory syncytial virus. BMC Infect Dis. 2022;22(1):108. doi:10.1186/s12879-022-07089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07089-9</ArticleId><ArticleId IdType="pmc">PMC8802536</ArticleId><ArticleId IdType="pubmed">35100984</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell CD, Fairfield CJ, Drake TM, et al. Co‐infections, secondary infections, and antimicrobial use in patients hospitalised with COVID‐19 during the first pandemic wave from the ISARIC WHO CCP‐UK study: a multicentre, prospective cohort study. Lancet Micr. 2021;2(8):e354‐e365. doi:10.1016/S2666-5247(21)00090-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00090-2</ArticleId><ArticleId IdType="pmc">PMC8172149</ArticleId><ArticleId IdType="pubmed">34100002</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID‐19: rapid review and meta‐analysis. Clin Microbiol Infect. 2021;27(4):520‐531. doi:10.1016/j.cmi.2020.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.12.018</ArticleId><ArticleId IdType="pmc">PMC7785281</ArticleId><ArticleId IdType="pubmed">33418017</ArticleId></ArticleIdList></Reference><Reference><Citation>Komagamine J, Yabuki T, Matsumoto K, Tanaka N. Evaluation of antimicrobial drug use and concurrent infections during hospitalization of patients with COVID‐19 in Japan. JAMA Netw Open. 2022;5(2):e220040. doi:10.1001/jamanetworkopen.2022.0040</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.0040</ArticleId><ArticleId IdType="pmc">PMC8857682</ArticleId><ArticleId IdType="pubmed">35179589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co‐infection between SARS‐CoV‐2 and other respiratory pathogens. Jama. 2020;323(20):2085‐2086. doi:10.1001/jama.2020.6266</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6266</ArticleId><ArticleId IdType="pmc">PMC7160748</ArticleId><ArticleId IdType="pubmed">32293646</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. Bacterial infections and patterns of antibiotic use in patients with COVID‐19. J Med Virol. 2021;93(3):1489‐1495. doi:10.1002/jmv.26441</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26441</ArticleId><ArticleId IdType="pmc">PMC7461450</ArticleId><ArticleId IdType="pubmed">32808695</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>